Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line
hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
Ju-Yeon Cho, Won Sohn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee
Korean J Intern Med. 2017;32(4):636-646. Published online 2016 Nov 4 DOI: https://doi.org/10.3904/kjim.2016.096
Citations to this article as recorded by 
Long-term entecavir therapy of chronic hepatitis B in real-life setting—Importance of quantitative HBsAg level
Gautam Ray
Indian Journal of Gastroenterology.2024; 43(3): 652. CrossRef
Outcomes of Entecavir Prophylaxis in Hepatitis B Immune Patients Receiving Hepatitis B Infected Kidneys: A Single Center Experience
Sameera Muqueet, Nikhil A. Reddy, Anna Curtis, Machaiah Madhrira, Sridhar R. Allam, Ashraf Reyad
Current Transplantation Reports.2024; 11(1): 15. CrossRef
Efficacy and its Predictors of Antiviral Therapy with Nucleos(T)Ide Analogs in Patients with Chronic Hepatitis B
T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk
The Russian Archives of Internal Medicine.2024; 14(2): 124. CrossRef
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
Sheila F Lumley, Marion Delphin, Jolynne F Mokaya, Cedric CS Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C Matthe
Journal of Clinical Virology.2024; : 105711. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
Hepatology.2023; 77(5): 1746. CrossRef
Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B
Joo Hyun Oh, Yewan Park, Myung Ji Goh, Dong Hyun Sinn, Sang Bong Ahn, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
Scientific Reports.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B
T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk, N. L. Bondarenko
Experimental and Clinical Gastroenterology.2023; (4): 77. CrossRef
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
Hepatology International.2022; 16(2): 294. CrossRef
Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression
Hankil Lee, Beom Kyung Kim, Sungin Jang, Sang Hoon Ahn
Clinical and Translational Gastroenterology.2021; 12(2): e00299. CrossRef
Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges
Blessing Dzingirai, Leolin Katsidzira, Celia Moffat Joel Matyanga, Maarten Jacobus Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
Journal of Viral Hepatitis.2021; 28(7): 994. CrossRef
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response
Ji Eun Na, Dong Hyun Sinn, Jeong‐Hoon Lee, Hee Joon Jang, Seon Yeong Baek, Kyung A Kim, Won Seok Kang, Geum‐Youn Gwak, Young‐Han Paik, Yoon Jun Kim, Moon Seok Choi, Jung‐Hwan Yoon, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Journal of Viral Hepatitis.2021; 28(10): 1392. CrossRef
Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study
Zhidan Zheng, Wei Liao, Lili Liu, Shaohang Cai, Haipeng Zhu, Sichun Yin
Biomedicine & Pharmacotherapy.2020; 122: 109698. CrossRef
Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan
Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Rie Mineta, Yukiko Suzuki, Hiromitsu Kumada
Journal of Gastroenterology.2019; 54(2): 182. CrossRef
Recent advances in assessment and treatment of chronic hepatitis B
Li Zhang, Fu-Kui Zhang
World Chinese Journal of Digestology.2019; 27(4): 209. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials
William W. L. Wong, Petros Pechivanoglou, Josephine Wong, Joanna M. Bielecki, Alex Haines, Aysegul Erman, Yasmin Saeed, Arcturus Phoon, Mina Tadrous, Mona Younis, Noha Z. Rayad, Valeria Rac, Harry L. A. Janssen, Murray D. Krahn
Systematic Reviews.2019;[Epub] CrossRef
Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy
Tien-Ching Lin, Yen-Cheng Chiu, Hung-Chih Chiu, Wen-Chun Liu, Pin-Nan Cheng, Chiung-Yu Chen, Ting-Tsung Chang, I-Chin Wu
World Journal of Gastroenterology.2018; 24(6): 725. CrossRef
Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
Sung Eun Kim
The Korean Journal of Internal Medicine.2017; 32(4): 631. CrossRef